Developer docs
API playgroundTry for free, no card

Search company profiles

Regor Therapeutics

Full company profile

uuid0000w48

Namestring
Regor Therapeutics
Legal namestring
Regor Therapeutics Group
Websiteurl
regor.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, small molecule drug discovery, GLP-1 receptor agonists, CDK inhibitors oncology, drug pipeline licensing
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Out-licensing and asset sales
TypeLicensing Royalties
Description

Regor out-licenses its proprietary drug candidates to large pharmaceutical companies for late-stage development and commercialization. Revenue comes from upfront payments, milestone payments, and royalties on net sales. Example: $850M upfront deal with Roche/Genentech for CDK inhibitor portfolio.

regor.com
2Clinical development partnerships
TypeLicensing Royalties
Description

Strategic collaborations with pharmaceutical partners for co-development of pipeline candidates through clinical stages, generating milestone payments and potential future royalties.

regor.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Regor Therapeutics is a clinical-stage biotechnology company that discovers and develops proprietary small molecule drug candidates in oncology, metabolism, and immunology using its proprietary rCARD drug discovery platform. The company advances candidates through preclinical and early clinical stages, then out-licenses or sells them to large pharmaceutical partners such as Roche/Genentech for late-stage development and commercialization, generating upfront payments, milestones, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2a topline results achieved for RGT-075 in obesity treatment
+2 more records
Product overview1 text field

Regor Therapeutics Group is a clinical-stage biotechnology company that operates as a drug discovery engine powered by its proprietary rCARD (Computer Accelerated Rational Discovery) platform. The company develops a pipeline of pre-clinical and clinical candidates across three therapeutic areas: metabolism, oncology, and immunology. The core products include RGT-075, a once-daily oral small molecule GLP-1R agonist for obesity in Phase II trials, and a portfolio of next-generation CDK inhibitors (RGT-419B and RGT-587) for breast cancer that have been out-licensed to Roche/Genentech. The rCARD platform integrates computational biology, structural biology, and computational chemistry to discover and optimize pre-clinical candidates before licensing to top pharmaceutical partners for clinical development and commercialization.

Product and service6 records
1RGT-419B (GDC-4198)
CategoryClinical-stage pharmaceutical asset
Description

Next-generation CDK inhibitor for breast cancer, targeting HR+/HER2- advanced breast cancer patients who have progressed on CDK4/6 inhibitors and endocrine therapy. Licensed to Roche/Genentech with Phase I trials in progress.

2RGT-587 (GDC-0587)
CategoryClinical-stage pharmaceutical asset
Description

Next-generation CDK inhibitor for breast cancer, part of the next-generation CDK inhibitor portfolio out-licensed to Roche/Genentech. Phase I trials in progress.

3RGT-075
CategoryClinical-stage pharmaceutical asset
Description

Once-daily oral small molecule GLP-1R agonist for the treatment of obesity and type 2 diabetes, demonstrating peptide-like efficacy and tolerability. Phase II trials in progress.

4rCARD Platform
CategoryDrug discovery technology platform
Description

Regor Computer Accelerated Rational Discovery (rCARD) platform that combines computational biology, structural biology, and computational chemistry for target identification, validation, and molecule design and optimization. Powers Regor's preclinical candidate discovery across metabolism, oncology, and immunology.

5RGT-068A
CategoryPreclinical pharmaceutical asset
Description

Preclinical MALT1 inhibitor developed using proprietary chemistry (direct construction of chiral ether via Heck reaction and N-directed asymmetric hydrogenation). Targeted at immunology/autoimmune indications.

6QR-6401
CategoryPreclinical pharmaceutical asset
Description

Macrocyclic CDK2 inhibitor discovered through generative models and structure-based drug design as a preclinical oncology asset.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-24
Description

Strategic collaboration to optimize Regor's proprietary rCARD platform for identification of novel targets and therapeutics. Sermonix and Regor are working together to advance the rCARD platform capabilities.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-09-30
Description

Regor entered into a definitive purchase agreement for Genentech to acquire Regor's portfolio of next-generation CDK inhibitors (RGT-419B/GDC-4198 and RGT-587/GDC-0587) for breast cancer treatment. Deal valued at $850M upfront payment with potential additional milestones.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing oral small molecule GLP-1R agonists for obesity and metabolic disease — the closest direct competitor to Regor's RGT-075 program, sharing the same differentiated oral-GLP-1 thesis and target patient population.

TypeDirect peer
Description

Operates a computational drug discovery platform (LiveDesign) used by multiple pharma partners — comparable to Regor's rCARD platform in combining physics-based simulation, ML, and structural biology to accelerate small molecule discovery and partnering.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with computational methods to generate a broad preclinical and clinical pipeline — analogous to Regor's platform-driven, asset-out-licensing model across multiple therapeutic areas.

TypeDirect peer
Description

AI-based drug discovery company using a precision design platform to advance partnered and wholly-owned candidates — shares Regor's platform-as-engine approach and reliance on pharma out-licensing/collaboration revenue.

TypeDirect peer
Description

Precision medicine biotech integrating computational methods (DYNAMO platform) with structural biology to develop targeted oncology therapies — comparable to Regor's rCARD-driven approach in oncology and CDK-targeted programs.

TypeDirect peer
Description

Clinical-stage biotech with a pipeline spanning obesity (oral GLP-1RA) and oncology — a direct competitor to Regor's RGT-075 program and shares the Asia-Pacific / US cross-border operating model.

TypeEmerging player
Description

Clinical-stage precision oncology biotech using a discovery platform to develop targeted therapies against resistance mutations — comparable to Regor's focus on next-generation kinase inhibitors addressing resistance in solid tumors.

TypeBroad incumbent
Description

Clinical-stage biotech with a broader targeted protein degradation platform and multiple pharma partnerships — comparable in business model (platform + partnered pipeline) but addresses different target classes than Regor's CDK and GLP-1 programs.

TypeEmerging player
Description

Clinical-stage precision oncology company developing kinase inhibitors for RAS/MAPK pathway cancers — overlaps with Regor's CDK inhibitor portfolio in oncology target class and clinical-stage out-licensing dynamic.

TypeEmerging player
Description

Early-stage platform biotech using chemoproteomics and computational chemistry to drug challenging targets — comparable to Regor in scale, platform-driven discovery approach, and partnership-oriented pipeline strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Regor Therapeutics

Biopharmaceuticalsregor.com

Regor Therapeutics firmographics

Firmographics
Name
Regor Therapeutics
Legal name
Regor Therapeutics Group
Website
https://regor.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where Regor Therapeutics is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices4 records

Markets served

Regor Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Out-licensing and asset sales: Regor out-licenses its proprietary drug candidates to large pharmaceutical companies for late-stage development and commercialization. Revenue comes from upfront payments, milestone payments, and royalties on net sales. Example: $850M upfront deal with Roche/Genentech for CDK inhibitor portfolio.
  2. Clinical development partnerships: Strategic collaborations with pharmaceutical partners for co-development of pipeline candidates through clinical stages, generating milestone payments and potential future royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Regor Therapeutics product offering

Product offering

Core offering

Regor Therapeutics is a clinical-stage biotechnology company that discovers and develops proprietary small molecule drug candidates in oncology, metabolism, and immunology using its proprietary rCARD drug discovery platform. The company advances candidates through preclinical and early clinical stages, then out-licenses or sells them to large pharmaceutical partners such as Roche/Genentech for late-stage development and commercialization, generating upfront payments, milestones, and royalties.

Product overview

Regor Therapeutics Group is a clinical-stage biotechnology company that operates as a drug discovery engine powered by its proprietary rCARD (Computer Accelerated Rational Discovery) platform. The company develops a pipeline of pre-clinical and clinical candidates across three therapeutic areas: metabolism, oncology, and immunology. The core products include RGT-075, a once-daily oral small molecule GLP-1R agonist for obesity in Phase II trials, and a portfolio of next-generation CDK inhibitors (RGT-419B and RGT-587) for breast cancer that have been out-licensed to Roche/Genentech. The rCARD platform integrates computational biology, structural biology, and computational chemistry to discover and optimize pre-clinical candidates before licensing to top pharmaceutical partners for clinical development and commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

  • RGT-419B (GDC-4198) Next-generation CDK inhibitor for breast cancer, targeting HR+/HER2- advanced breast cancer patients who have progressed on CDK4/6 inhibitors and endocrine therapy. Licensed to Roche/Genentech with Phase I trials in progress.
  • RGT-587 (GDC-0587) Next-generation CDK inhibitor for breast cancer, part of the next-generation CDK inhibitor portfolio out-licensed to Roche/Genentech. Phase I trials in progress.
  • RGT-075 Once-daily oral small molecule GLP-1R agonist for the treatment of obesity and type 2 diabetes, demonstrating peptide-like efficacy and tolerability. Phase II trials in progress.
  • rCARD Platform Regor Computer Accelerated Rational Discovery (rCARD) platform that combines computational biology, structural biology, and computational chemistry for target identification, validation, and molecule design and optimization. Powers Regor's preclinical candidate discovery across metabolism, oncology, and immunology.
  • RGT-068A Preclinical MALT1 inhibitor developed using proprietary chemistry (direct construction of chiral ether via Heck reaction and N-directed asymmetric hydrogenation). Targeted at immunology/autoimmune indications.
  • QR-6401 Macrocyclic CDK2 inhibitor discovered through generative models and structure-based drug design as a preclinical oncology asset.

Quantifiable outcome

  • Phase 2a topline results achieved for RGT-075 in obesity treatment
  • +2 more outcomes

Companies that use Regor Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Regor Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Regor Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and flagship.

  • SermonixcoreStrategic or Co-development Partner · 24 March 2025Strategic collaboration to optimize Regor's proprietary rCARD platform for identification of novel targets and therapeutics. Sermonix and Regor are working together to advance the rCARD platform capabilities.
  • Genentech (Roche)flagshipOEM/ Whitelabel/ Licensing Partner · 30 September 2024Regor entered into a definitive purchase agreement for Genentech to acquire Regor's portfolio of next-generation CDK inhibitors (RGT-419B/GDC-4198 and RGT-587/GDC-0587) for breast cancer treatment. Deal valued at $850M upfront payment with potential additional milestones.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Regor Therapeutics competitors and assessment

Company assessment

Direct peers

  • Structure Therapeutics: Clinical-stage biotech developing oral small molecule GLP-1R agonists for obesity and metabolic disease — the closest direct competitor to Regor's RGT-075 program, sharing the same differentiated oral-GLP-1 thesis and target patient population.
  • Schrödinger, Inc. Operates a computational drug discovery platform (LiveDesign) used by multiple pharma partners — comparable to Regor's rCARD platform in combining physics-based simulation, ML, and structural biology to accelerate small molecule discovery and partnering.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with computational methods to generate a broad preclinical and clinical pipeline — analogous to Regor's platform-driven, asset-out-licensing model across multiple therapeutic areas.
  • Exscientia: AI-based drug discovery company using a precision design platform to advance partnered and wholly-owned candidates — shares Regor's platform-as-engine approach and reliance on pharma out-licensing/collaboration revenue.
  • Relay Therapeutics: Precision medicine biotech integrating computational methods (DYNAMO platform) with structural biology to develop targeted oncology therapies — comparable to Regor's rCARD-driven approach in oncology and CDK-targeted programs.
  • Terns Pharmaceuticals: Clinical-stage biotech with a pipeline spanning obesity (oral GLP-1RA) and oncology — a direct competitor to Regor's RGT-075 program and shares the Asia-Pacific / US cross-border operating model.

Emerging players

  • Black Diamond Therapeutics: Clinical-stage precision oncology biotech using a discovery platform to develop targeted therapies against resistance mutations — comparable to Regor's focus on next-generation kinase inhibitors addressing resistance in solid tumors.
  • Erasca: Clinical-stage precision oncology company developing kinase inhibitors for RAS/MAPK pathway cancers — overlaps with Regor's CDK inhibitor portfolio in oncology target class and clinical-stage out-licensing dynamic.
  • Frontier Medicines: Early-stage platform biotech using chemoproteomics and computational chemistry to drug challenging targets — comparable to Regor in scale, platform-driven discovery approach, and partnership-oriented pipeline strategy.

Broad incumbents

  • Arvinas: Clinical-stage biotech with a broader targeted protein degradation platform and multiple pharma partnerships — comparable in business model (platform + partnered pipeline) but addresses different target classes than Regor's CDK and GLP-1 programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Regor Therapeutics social profiles

Digital presence

Regor Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Regor Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Regor Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Regor Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regor Therapeutics

What does Regor Therapeutics do?

Regor Therapeutics is a clinical-stage biotechnology company that discovers and develops proprietary small molecule drug candidates in oncology, metabolism, and immunology using its proprietary rCARD drug discovery platform. The company advances candidates through preclinical and early clinical stages, then out-licenses or sells them to large pharmaceutical partners such as Roche/Genentech for late-stage development and commercialization, generating upfront payments, milestones, and royalties.

Is Regor Therapeutics a public or private company?

Regor Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Regor Therapeutics founded?

Regor Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is Regor Therapeutics based?

Regor Therapeutics is headquartered in Shanghai, China, in the Asia region.

How does Regor Therapeutics make money?

Two revenue lines are on record. Out-licensing and asset sales are the primary driver. The others are clinical development partnerships.

Who are Regor Therapeutics's main competitors?

Direct peers on record are Structure Therapeutics, Schrödinger, Inc., Recursion Pharmaceuticals, Exscientia, Relay Therapeutics and Terns Pharmaceuticals. Emerging players are Black Diamond Therapeutics, Erasca and Frontier Medicines. Arvinas is listed as a broad incumbent.

Does Regor Therapeutics have an API?

No public API is recorded for Regor Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and TherapeuticsSermonix Pharmaceuticals and Regor Therapeutics Group announced a strategic collaboration on March 24, 2025, to optimize Regor's proprietary rCARD™ computational drug discovery platform for identifying novel targets and therapeutics in metastatic breast cancer. The partnership combines Sermonix's Phase 3 asset lasofoxifene and clinical commercialization expertise with Regor's AI-driven small molecule discovery engine to develop treatments addressing efficacy, tolerability, and patient quality of life concerns. The companies aim to fill unmet needs in onco-sexuality, cardio-oncology, and bone health as breast cancer care evolves from a lethal to a chronic disease paradigm.PR NewswireRegor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of ObesityRegor Therapeutics announced positive Phase 2a topline results for RGT-075, an oral once-daily small molecule GLP-1 receptor agonist for obesity, showing 5% placebo-adjusted weight loss at 12 weeks with no plateau and a 4% discontinuation rate matching placebo. The company has initiated the COMO-1 Phase 2b dose-finding trial expected to read out in Q4 2025, evaluating doses up to 225 mg over 36 weeks in approximately 240 participants. Regor stated it has the financial means to launch Phase 3 programs independently following a recent $850M upfront deal with Roche for CDK oncology agents.BioWorldQilu Regor Therapeutics discloses new CDK2 inhibitorsQilu Regor Therapeutics Inc. has patented cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer. The patent was disclosed on October 25, 2022, and the company has not provided further details on the inhibitors.FierceBiotechPfizer accuses former employees of 'treachery' in stealing trade secrets to form Regor TherapeuticsPfizer filed a lawsuit accusing former employees Min Zhong and Xiayang Qiu of stealing trade secrets to launch Regor Therapeutics, which subsequently secured a $1.5 billion deal with Eli Lilly for metabolic disease therapies. Pfizer alleges that the ex-employees misappropriated confidential data from its GLP-1 program before departing in 2018, providing an unlawful advantage to their new venture. The complaint seeks legal recourse under federal and Connecticut trade secret laws for the alleged theft of intellectual property.PR NewswireRegor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for OncologyRegor Therapeutics received authorization from the U.S. Food and Drug Administration to initiate Phase 1 clinical trials for RGT-419B, a next-generation targeted inhibitor for oncology. The drug is designed to address resistance to current CDK4/6 inhibitors in patients with hormone receptor-positive, HER2-negative breast cancer.PR NewswireLilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic DisordersEli Lilly and Company and Regor Therapeutics Group announced on December 10, 2021, a multi-year research collaboration and licensing agreement to discover, develop, and commercialize novel therapies for metabolic disorders. Regor will receive an upfront payment of up to $50 million and could receive up to $1.5 billion in potential milestone payments plus tiered royalties, while Lilly will be responsible for global clinical development, manufacturing, and commercialization outside China, Macau, Hong Kong, and Taiwan. The collaboration aims to leverage both companies' compounds and technologies to expand treatment options for patients with metabolic disorders such as diabetes and obesity.BenzingaThe Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine DThis article provides a roundup of recent developments in the biotech sector, highlighting multiple corporate announcements including clinical trial results, strategic collaborations, and financial updates. Key events include Eli Lilly's licensing pact with Regor Therapeutics for metabolic disorder therapies, Moderna's positive interim data for its flu vaccine candidate, and SpringWorks Therapeutics' collaboration with AbbVie for a blood cancer drug study. Other reported activities involve Angion Biomedica's failed trial endpoint, OncoCyte's diagnostic test data, BeiGene's positive nasopharyngeal cancer results, Halozyme's stock buyback program, and Applied DNA Sciences' earnings report.https://www.avcj.comChina's Regor Therapeutics raises $90m Series BLilly Asia Ventures led a $90 million Series B round for Regor Therapeutics, a Chinese drug developer. The company has advanced four projects to pre-clinical stage within 12 months, focusing on cancer, immune disorders, and metabolic diseases. The funding follows a 2018 seed commitment from Qilu Pharmaceutical Group.FinSMEsRegor Therapeutics Closes $90M Series B FinancingRegor Therapeutics, a Shanghai-based biotech, closed a $90M Series B financing led by Lilly Asia Ventures, with participation from Loyal Valley Capital, Lanting Capital, TF Capital, and Vertex Ventures China. The company was founded in 2018 by Dr. Xiayang Qiu and uses a proprietary CARD platform for drug discovery.PR NewswireRegor Therapeutics Announces Completion of $90 Million Series B FinancingRegor Therapeutics announced the successful completion of a $90 million Series B financing round led by Lilly Asia Ventures. The investment, which also included participation from Loyal Valley Capital, Lanting Capital, TF Capital, and Vertex Ventures China, will support the company's pre-clinical and clinical studies for multiple drug programs.